Return on equity of Exelixis, Inc.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company??s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
|Company||Industry||Return on equity|
|BUFF Blue Buffalo Pet Products, Inc.||NASDAQ > Consumer Non-Durables > Packaged Foods||99.01%|
|ABBV AbbVie Inc.||NYSE > Health Care > Major Pharmaceuticals||101.06%|
|MLP Maui Land & Pineapple Company, Inc.||NYSE > Finance > Real Estate||107.04%|
|NES Nuverra Environmental Solutions, Inc.||NYSEMKT > Energy > Oilfield Services/Equipment||109.19%|
|SPGI S&P Global Inc.||NYSE > Finance > Finance: Consumer Services||109.50%|
|AMCX AMC Networks Inc.||NASDAQ > Consumer Services > Television Services||109.83%|
|EXEL Exelixis, Inc.||NASDAQ > Health Care > Biotechnology: Commercial Physical & Biological Resarch||111.45%|
|OPNT Opiant Pharmaceuticals, Inc.||NASDAQ > Basic Industries > Precious Metals||2,031.11%|
|PBT Permian Basin Royalty Trust||NYSE > Energy > Oil & Gas Production||4,888.60%|
|IDXX IDEXX Laboratories, Inc.||NASDAQ > Health Care > Biotechnology: In Vitro & In Vivo Diagnostic Substances||8,410.92%|
|NRT North European Oil Royality Trust||NYSE > Energy > Oil & Gas Production||8,437.44%|
|CQH Cheniere Energy Partners LP Holdings, LLC||NYSEMKT > Public Utilities > Oil/Gas Transmission||9,523.81%|
|BPT BP Prudhoe Bay Royalty Trust||NYSE > Energy > Integrated oil Companies||9,929.09%|